{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:02:36Z","timestamp":1790960556430,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00277-021-04690-x","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T10:02:40Z","timestamp":1640685760000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review"],"prefix":"10.1007","volume":"101","author":[{"given":"Paola","family":"Ghanem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Marrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Shanbhag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"Brahmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5562-1283","authenticated-orcid":false,"given":"Rakhi P.","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,28]]},"reference":[{"issue":"26","key":"4690_CR1","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455\u20132465","journal-title":"N Engl J Med"},{"issue":"7528","key":"4690_CR2","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568\u2013571","journal-title":"Nature"},{"issue":"2","key":"4690_CR3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S1074-7613(02)00362-X","volume":"17","author":"AV Collins","year":"2002","unstructured":"Collins AV et al (2002) The interaction properties of costimulatory molecules revisited. Immunity 17(2):201\u2013210","journal-title":"Immunity"},{"issue":"21","key":"4690_CR4","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","volume":"25","author":"RV Parry","year":"2005","unstructured":"Parry RV et al (2005) CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 25(21):9543\u20139553","journal-title":"Mol Cell Biol"},{"key":"4690_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.lungcan.2016.06.026","volume":"99","author":"S Tabchi","year":"2016","unstructured":"Tabchi S, Weng X, Blais N (2016) Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab. Lung Cancer 99:123\u2013126","journal-title":"Lung Cancer"},{"key":"4690_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ejca.2020.02.043","volume":"131","author":"S Matsumoto","year":"2020","unstructured":"Matsumoto S et al (2020) A case of recurrent thrombocytopenia involving divergent immune-related mechanisms associated with pembrolizumab. Eur J Cancer 131:104\u2013107","journal-title":"Eur J Cancer"},{"issue":"2","key":"4690_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.7326\/M17-2073","volume":"168","author":"N Abdel-Wahab","year":"2018","unstructured":"Abdel-Wahab N et al (2018) Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med 168(2):121\u2013130","journal-title":"Ann Intern Med"},{"issue":"17","key":"4690_CR8","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36(17):1714\u20131768","journal-title":"J Clin Oncol"},{"issue":"5","key":"4690_CR9","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","volume":"24","author":"EJ Davis","year":"2019","unstructured":"Davis EJ et al (2019) Hematologic complications of immune checkpoint inhibitors. Oncologist 24(5):584\u2013588","journal-title":"Oncologist"},{"key":"4690_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2018.07.129","volume":"103","author":"F Petrelli","year":"2018","unstructured":"Petrelli F et al (2018) Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. Eur J Cancer 103:7\u201316","journal-title":"Eur J Cancer"},{"issue":"1","key":"4690_CR11","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","volume":"6","author":"N Delanoy","year":"2019","unstructured":"Delanoy N et al (2019) Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol 6(1):e48\u2013e57","journal-title":"Lancet Haematol"},{"issue":"2","key":"4690_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/ejh.13187","volume":"102","author":"GE Tanios","year":"2019","unstructured":"Tanios GE, Doley PB, Munker R (2019) Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review. Eur J Haematol 102(2):157\u2013162","journal-title":"Eur J Haematol"},{"issue":"7","key":"4690_CR13","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1634\/theoncologist.2017-0531","volume":"23","author":"S Parakh","year":"2018","unstructured":"Parakh S, Cebon J, Klein O (2018) Delayed autoimmune toxicity occurring several months after cessation of anti-PD-1 therapy. Oncologist 23(7):849\u2013851","journal-title":"Oncologist"},{"issue":"9","key":"4690_CR14","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1001\/jamadermatol.2018.1912","volume":"154","author":"LL Wang","year":"2018","unstructured":"Wang LL et al (2018) Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy. JAMA Dermatol 154(9):1057\u20131061","journal-title":"JAMA Dermatol"},{"issue":"19","key":"4690_CR15","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR et al (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28(19):3167\u20133175","journal-title":"J Clin Oncol"},{"issue":"10","key":"4690_CR16","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1080\/17425255.2016.1216976","volume":"12","author":"TC Longoria","year":"2016","unstructured":"Longoria TC, Tewari KS (2016) Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol 12(10):1247\u20131253","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"4690_CR17","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1158\/2326-6066.CIR-15-0210","volume":"4","author":"A Ribas","year":"2016","unstructured":"Ribas A et al (2016) PD-1 blockade expands intratumoral memory T cells. Cancer Immunol Res 4(3):194\u2013203","journal-title":"Cancer Immunol Res"},{"key":"4690_CR18","doi-asserted-by":"crossref","unstructured":"Osa A, Uenami T, Koyama S, Fujimoto K, Okuzaki D, Takimoto T, Kumanogoh A (2018) Clinical implications of monitoring nivolumab immunokinetics in non\u2013small cell lung cancer patients. JCI insight 3(19)","DOI":"10.1172\/jci.insight.59125"},{"issue":"4","key":"4690_CR19","first-page":"875","volume":"35","author":"MP Tardy","year":"2017","unstructured":"Tardy MP et al (2017) Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report Hematol Oncol 35(4):875\u2013877","journal-title":"A case report Hematol Oncol"},{"issue":"5","key":"4690_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/ajh.25448","volume":"94","author":"RK Leaf","year":"2019","unstructured":"Leaf RK et al (2019) Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. Am J Hematol 94(5):563\u2013574","journal-title":"Am J Hematol"},{"key":"4690_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139\u2013148","journal-title":"Eur J Cancer"},{"issue":"11","key":"4690_CR22","doi-asserted-by":"publisher","first-page":"7316","DOI":"10.4049\/jimmunol.179.11.7316","volume":"179","author":"D Quandt","year":"2007","unstructured":"Quandt D et al (2007) A new role of CTLA-4 on B cells in thymus-dependent immune responses in vivo. J Immunol 179(11):7316\u20137324","journal-title":"J Immunol"},{"issue":"7","key":"4690_CR23","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1097\/CAD.0000000000000520","volume":"28","author":"I Turgeman","year":"2017","unstructured":"Turgeman I et al (2017) Severe complicated neutropenia in two patients with metastatic non-small-cell lung cancer treated with nivolumab. Anticancer Drugs 28(7):811\u2013814","journal-title":"Anticancer Drugs"},{"issue":"3","key":"4690_CR24","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/CJI.0b013e31819aa40b","volume":"32","author":"M Akhtari","year":"2009","unstructured":"Akhtari M et al (2009) Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother 32(3):322\u2013324","journal-title":"J Immunother"},{"key":"4690_CR25","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/1752-1947-8-240","volume":"8","author":"E Simeone","year":"2014","unstructured":"Simeone E et al (2014) Serious haematological toxicity during and after ipilimumab treatment: a case series. J Med Case Rep 8:240","journal-title":"J Med Case Rep"},{"issue":"8","key":"4690_CR26","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00262-008-0627-x","volume":"58","author":"IO Gordon","year":"2009","unstructured":"Gordon IO et al (2009) Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother 58(8):1351\u20131353","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"4690_CR27","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1093\/annonc\/mdx177","volume":"28","author":"H Helgadottir","year":"2017","unstructured":"Helgadottir H et al (2017) Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma. Ann Oncol 28(7):1672\u20131673","journal-title":"Ann Oncol"},{"issue":"2","key":"4690_CR28","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1093\/annonc\/mdx693","volume":"29","author":"L Leroy","year":"2018","unstructured":"Leroy L et al (2018) A fatal allo- and immune-mediated thrombocytopenia with a PD-L1 inhibitor. Ann Oncol 29(2):514\u2013515","journal-title":"Ann Oncol"},{"issue":"2","key":"4690_CR29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/1078155211411001","volume":"18","author":"S Ahmad","year":"2012","unstructured":"Ahmad S et al (2012) Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma. J Oncol Pharm Pract 18(2):287\u2013292","journal-title":"J Oncol Pharm Pract"},{"issue":"9","key":"4690_CR30","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1056\/NEJMoa030254","volume":"349","author":"Y Cheng","year":"2003","unstructured":"Cheng Y et al (2003) Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 349(9):831\u2013836","journal-title":"N Engl J Med"},{"issue":"15","key":"4690_CR31","doi-asserted-by":"publisher","first-page":"9072","DOI":"10.1200\/jco.2013.31.15_suppl.9072","volume":"31","author":"MZ Sajjad","year":"2013","unstructured":"Sajjad MZ et al (2013) Thrombocytopenia associated with ipilimumab therapy of advanced melanoma at a single institution. J Clin Oncol 31(15):9072\u20139072","journal-title":"J Clin Oncol"},{"key":"4690_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-017-0210-0","volume":"5","author":"E Shiuan","year":"2017","unstructured":"Shiuan E et al (2017) Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J Immunother Cancer 5:8","journal-title":"J Immunother Cancer"},{"key":"4690_CR33","first-page":"17","volume":"21","author":"D Atwal","year":"2017","unstructured":"Atwal D et al (2017) Pembrolizumab-induced pancytopenia: a case report. Perm J 21:17\u2013004","journal-title":"Perm J"},{"key":"4690_CR34","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ejca.2015.10.073","volume":"54","author":"A Le Roy","year":"2016","unstructured":"Le Roy A et al (2016) Two cases of immune thrombocytopenia associated with pembrolizumab. Eur J Cancer 54:172\u2013174","journal-title":"Eur J Cancer"},{"issue":"1","key":"4690_CR35","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s40425-019-0648-3","volume":"7","author":"AR Naqash","year":"2019","unstructured":"Naqash AR et al (2019) Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition. J Immunother Cancer 7(1):169","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4690_CR36","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/1078155217726159","volume":"25","author":"RR Comito","year":"2019","unstructured":"Comito RR, Badu LA, Forcello N (2019) Nivolumab-induced aplastic anemia: a case report and literature review. J Oncol Pharm Pract 25(1):221\u2013225","journal-title":"J Oncol Pharm Pract"},{"key":"4690_CR37","doi-asserted-by":"crossref","unstructured":"Shaikh H, Daboul N, Albrethsen M, Fazal S (2018) A case of autoimmune haemolytic anaemia after 39 cycles of nivolumab. Case Reports, bcr-2018","DOI":"10.1136\/bcr-2018-224608"},{"key":"4690_CR38","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejca.2019.02.006","volume":"112","author":"M Berger","year":"2019","unstructured":"Berger M et al (2019) A case of immune thrombocytopaenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia. Eur J Cancer 112:94\u201397","journal-title":"Eur J Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04690-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04690-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04690-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T15:10:23Z","timestamp":1641222623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04690-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,28]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["4690"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04690-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,28]]},"assertion":[{"value":"21 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Paola Ghanem has no financial or non-financial interests to disclose. Satish Shanbhag has received consulting fees from Takeda oncology, GSK, Daiichi-Sankyo, Kura oncology, Celgene, Beigene, and institutional research grant support from Daiichi Sankyo. Kristen Marrone consulted and was part of the advisory boards for AstraZeneca and Amgen. Julie R. Brahmer is a consultant for Merck, Bristol Myers Squibb, Genentech\/Roche, Amgen, GlaxoSmithKline, AstraZeneca, Eli Lilly, Sanofi, and Regeneron. Julie R. Brahmer has received grant funding from AstraZeneca and Bristol Myers Squib. Rakhi P. Naik has received funding from Rigel pharmaceuticals. All disclosures are unrelated to the subject matter of this manuscript. The authors did not receive support from any organization for the submitted work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}